3/2/2021 11:46:12 PM
KemPharm: FDA Approves AZSTARYS For Attention Deficit Hyperactivity Disorder In Patients Age Six Years And Older
5/19/2020 7:35:44 AM
KemPharm Receives Day-74 Letter For KP415 NDA; FDA Sets PDUFA Date Of March 2, 2021
2/28/2020 7:35:20 AM
KemPharm Q4 Net Loss $6.0 Mln Or $0.18 Per Share
11/10/2016 6:46:54 AM
RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) Q4 16 Estimate To -0.76 From -0.68
11/10/2016 6:46:28 AM
RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) 2018 Estimate To -1.92 From -1.85
11/10/2016 6:46:15 AM
RBC Capital Markets Is Cutting KEMPHARM, INC (KMPH) 2017 Estimate To -2.93 From -2.83
11/10/2016 6:46:01 AM
RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) 2016 Estimate To -2.47 From -2.20
3/11/2016 8:00:46 AM
RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) FY18 Estimate To 0.72 From 0.76
3/11/2016 8:00:28 AM
RBC Capital Markets Is Cutting KEMPHARM, INC (KMPH) FY17 Estimate To -2.53 From -1.97
3/11/2016 8:00:11 AM
RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) FY16 Estimate To -3.14 From -2.23